Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial

Highlight

• Both transcatheter (TAVR) and surgical aortic valve replacement (SAVR) significantly improve health status in low-risk aortic stenosis patients, sustained up to 7 years.
• TAVR leads to significantly faster early recovery in quality of life at 1 month compared to SAVR, with benefits persisting modestly up to 2 years.
• From years 3 to 7, patient-reported health status outcomes converge, showing no significant differences between TAVR and SAVR groups.
• About 60% of patients in either group maintain excellent health status at 7 years, emphasizing long-term durability of both interventions.

Study Background and Disease Burden